Exclusive Summary

• Optimal dual-strength for omni-channel coverage: 0.4mg perfectly meets the rigid global maternal demand for NTD prevention, while 5mg addresses megaloblastic anemia and standard adjunct rescue therapy for Rheumatoid Arthritis patients.
• Zero patent barriers & top guideline endorsements: Listed on the WHO Essential Medicines List globally with no patent restrictions, and strictly advocated by top gynecological and rheumatological guidelines globally, ensuring zero market education cost.
• Ultimate cost edge & API supply chain moat: Leveraging China's absolute market dominance in global Folic Acid API manufacturing, the tablets hold an unparalleled price advantage, ideal for aggressively winning public health tenders and maximizing retail profit margins.
• Fast regulatory pathways & versatile bundling driver: Backed by ready-to-file standard CTD dossiers to accelerate local approvals for overseas distributors; serves as an indispensable volume-driver baseline product for portfolio bidding.